Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference
Mersana Therapeutics, Inc. will participate in a fireside chat at Guggenheim’s 6th Annual Biotechnology Conference on February 8, 2024. The company is a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need.
02/01/2024 - 08:00 AM
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in a fireside chat at Guggenheim’s 6th Annual Biotechnology Conference on February 8, 2024 at 11:30 a.m. ET. A live webcast of this event will be available on the Investors & Media section of Mersana’s website at www.mersana.com , and an archived replay will be available for approximately 90 days following the event.
About Mersana Therapeutics Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com .
Contact: Jason Fredette 617-498-0020jason.fredette@mersana.com
What is Mersana Therapeutics, Inc. participating in on February 8, 2024?
Mersana Therapeutics, Inc. will participate in a fireside chat at Guggenheim’s 6th Annual Biotechnology Conference on February 8, 2024.
What is the focus of Mersana Therapeutics, Inc. as a company?
Mersana Therapeutics, Inc. is focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need.
Where can the live webcast of Mersana Therapeutics, Inc.'s event be accessed?
A live webcast of the event will be available on the Investors & Media section of Mersana’s website at www.mersana.com.
MRSN Rankings
#5398 Ranked by Stock Gains
MRSN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Cambridge
About MRSN
mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.